Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Restructuring Of China General Technology And Henan Topfond Pharmaceutical Group Delayed

This article was originally published in PharmAsia News

Executive Summary

China General Technology and Henan Topfond Pharmaceutical Group are still waiting for the approval of State-owned Assets Supervision and Administration Commission of the State Council for their restructuring (PharmAsia News, Jun. 2, 2008). According to the agreement, China General Technology will inject the initial funds into Topfond when the business registration changes. The delay is putting pressure on the latter's finances, whose liabilities have hit RMB 1.7 billion. When questioned about whether the deal will go through, Topfond expressed confidence in getting the approval as the restructuring represents transfer between state-owned assets. With total equity of RMB 2.6 billion and net assets of RMB 800 million, the firm's assets-liabilities ratio of 65 percent is still within the normal range. (Click here for more - Chinese Language)

You may also be interested in...

China General Technology To Acquire Henan Topfond Pharmaceutical

Henan Topfond Pharmaceutical Group will be transferring all its stake in Henan Topfond Pharmaceutical to state-owned China General Technology (Group) Holding (Genertec). Topfond Pharmaceutical needs funds urgently, while cash-rich Genertec has no pharmaceutical assets. The latter has been courting another drug company, Huabei Pharmaceutical, for some time but without success. According to sources, Genertec will inject approximately 3 billion yuan into Topfond to incorporate it as a development platform for pharmaceutical business. However, the deal needs the approval of State-owned Assets Supervision and Administration Commission of the State Council. To date, both parties have not signed any official collaboration agreement. (Click here for more - Chinese Language)

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts